Shares of Athenex, Inc. (NASDAQ:ATNX) have been given a consensus broker rating score of 2.00 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company.

Analysts have set a 12-month consensus price target of $25.73 for the company, according to Zacks. Zacks has also given Athenex an industry rank of 167 out of 265 based on the ratings given to related companies.

Several brokerages have recently issued reports on ATNX. Laidlaw began coverage on shares of Athenex in a research note on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price objective on the stock. Credit Suisse Group began coverage on shares of Athenex in a research note on Monday, September 18th. They issued an “outperform” rating and a $25.00 price objective on the stock. Royal Bank Of Canada began coverage on shares of Athenex in a research note on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price objective on the stock. J P Morgan Chase & Co assumed coverage on shares of Athenex in a research note on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price objective on the stock. Finally, Deutsche Bank AG assumed coverage on shares of Athenex in a research note on Monday, July 10th. They set a “buy” rating and a $20.00 price target on the stock.

Athenex (ATNX) opened at $16.77 on Friday. The company has a quick ratio of 3.44, a current ratio of 3.78 and a debt-to-equity ratio of 0.04.

Athenex (NASDAQ:ATNX) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.88) earnings per share (EPS) for the quarter. The firm had revenue of $4.60 million for the quarter. equities analysts forecast that Athenex will post -1.69 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new stake in Athenex during the second quarter worth $601,000. Tudor Investment Corp ET AL acquired a new stake in Athenex during the second quarter worth $320,000. OxFORD Asset Management LLP acquired a new stake in Athenex during the second quarter worth $956,000. California Public Employees Retirement System acquired a new stake in Athenex during the second quarter worth $800,000. Finally, Vanguard Group Inc. acquired a new stake in Athenex during the second quarter worth $800,000. Hedge funds and other institutional investors own 1.10% of the company’s stock.

WARNING: “Zacks: Athenex, Inc. (ATNX) Receives Consensus Rating of “Buy” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/11/04/zacks-athenex-inc-atnx-receives-consensus-rating-of-buy-from-analysts.html.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.